Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citigroup Inc. (C) vs GeneDx Holdings Corp (WGS) Price & Performance

Citigroup Inc.Trade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Citigroup Inc. vs GeneDx Holdings Corp — how do they compare? Citigroup Inc. trades at $135.95 (market cap $226.82B), while GeneDx Holdings Corp trades at $81.74 (market cap $2.32B). The key difference: Citigroup Inc. is far larger — about 97.8× GeneDx Holdings Corp's market cap, and Citigroup Inc. pays a 1.98% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.

CWGS
Market Cap
$226.82B$2.32B
Sector
FinancialsTechnology
52-Week High
$145.67$167.51
52-Week Low
$92.59$34.51
Dividend Yield
1.98%
Enterprise Value
$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citigroup Inc.

Citigroup (C) trades at $134.99, up 0.86% with bullish technical momentum near key resistance at $136. The stock shows strong fundamental improvement with Q2 2026 EPS beating estimates at $3.15 versus $2.72 expected, marking the second consecutive quarterly beat. Revenue reached decade highs in Q2 2026 at $91.4B with net income margin improving to 19.52%. Recent strategic hires in investment banking and digital transformation initiatives support growth prospects.

The outlook remains positive with analyst consensus target of $154.38 offering 14% upside potential. Key risks include volatile cash flow patterns with negative operating cash flow in 2025 ($-67.6B) and elevated debt levels at $287.3B long-term debt. The stock's current P/E of 14.55 appears reasonable given improving profitability and strategic repositioning underway.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citigroup Inc.

Citigroup Inc. is a diversified financial services holding company that provides a broad range of financial services to consumer and corporate customers. The Company services include investment banking, retail brokerage, corporate banking, and cash management products and services. Citigroup serves customers globally.

Read more on C

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS